Author's posts
Biden’s Plan To Expand Broadband Will Be A Huge Help To Older Adults
While much of the attention on expanded broadband is focused on how it will help young families with children, it also will improve access to medical care and monitoring as well as social supports and services—critical benefits for older adults who hav…
Are Critics Of Private Equity Nursing Home Ownership Living In The Past?
Industry experts tell me that, increasingly, big investors in senior services are abandoning nursing facilities in favor of the far more lucrative home health business and, in some cases, private-pay senior housing.
A Blue-Ribbon Panel Calls Nursing Home Care “Ineffective, Inefficient, Fragmented, And Unsustainable”
The National Academies of Science, Engineering, and Medicine has issued a scathing report on the state of nursing homes in the US. “The way in which the United States finances, delivers, and regulates care in nursing home settings is ineffective, ineff…
Aging In Place Is All The Rage, But It Is Not Easy
It has become increasingly popular to promote home as a setting for both sophisticated medical treatment and long-term care, and often for good reason. But supporters need to recognize the burden it places on families who must take on ever-challenging …
Biden Proposes Major Nursing Home Reforms
They include efforts to require minimum staffing levels; limit shared rooms; enhance inspections, penalties, and transparency; and crack down on owners with a history of poor quality.
How Nursing Home Staff Shortages Are Hurting Hospital Care
By now, you’ve probably heard about the desperate shortage of nurses and aides in nursing homes and long-term care facilities.
How The Medical System Is Failing People With Down Syndrome And Alzheimer’s Disease
As they live longer, up to ninety percent of people with Down Syndrome will have Alzheimer’s Disease.
Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial
In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Even After Covid, Could Congress Ignore The Long-Term Care Needs Of Older Adults?
Is it possible that Congress will do nothing to improve long-term services and supports for older adults and younger people with disabilities or assist their families? Even after 603,000 people over age 65 were killed by Covid-19 in the past two years.
What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?
This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm.
